U.S. Department of Defense Awards Rafa Laboratories Production FOLLOW-ON Agreement of over $45 million

The Advanced Anticonvulsant System (AAS) - Midazolam autoinjector, delivers enhanced capability to warfighters. This first in market product was developed by Rafa in cooperation with the U.S.

Related Keywords

Jerusalem ,Israel General ,Israel ,United States ,American ,Dennis Riedl ,Troy Shay ,Us Department Of Defense ,American Epilepsy Society ,Drug Administration ,Program Executive Office For Chemical ,Prnewswire Rafa Laboratories ,Nuclear Defense ,Head Of Emergency Solutions At Rafa ,Defense Department ,Advanced Anticonvulsant System ,Joint Program Executive Office ,Midazolam Injection ,Joint Force ,Convulsant Antidote ,Nerve Agent ,Midazolam Intramuscular ,United Therapeutics ,Emergency Solutions ,Department ,Defense ,Awards ,Dafa ,Laboratories ,Production ,Follow ,Agreement ,Dover ,Billion ,